Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.

Venter WDF, Moorhouse M, Sokhela S, Fairlie L, Mashabane N, Masenya M, Serenata C, Akpomiemie G, Qavi A, Chandiwana N, Norris S, Chersich M, Clayden P, Abrams E, Arulappan N, Vos A, McCann K, Simmons B, Hill A.

N Engl J Med. 2019 Aug 29;381(9):803-815. doi: 10.1056/NEJMoa1902824. Epub 2019 Jul 24.

PMID:
31339677
2.

Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial.

Venter WDF, Moorhouse M, Sokhela S, Serenata C, Akpomiemie G, Qavi A, Mashabane N, Arulappan N, Sim JW, Sinxadi PZ, Wiesner L, Maharaj E, Wallis C, Boyles T, Ripin D, Stacey S, Chitauri G, Hill A.

Lancet HIV. 2019 Jul;6(7):e428-e437. doi: 10.1016/S2352-3018(19)30081-5. Epub 2019 Jun 12.

PMID:
31202690
3.

Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Low-Dose Stavudine Over 96 Weeks: A Multicountry Randomized, Noninferiority Trial.

Venter WDF, Kambugu A, Chersich MF, Becker S, Hill A, Arulappan N, Moorhouse M, Majam M, Akpomiemie G, Sokhela S, Poongulali S, Feldman C, Duncombe C, Ripin DHB, Vos A, Kumarasamy N.

J Acquir Immune Defic Syndr. 2019 Feb 1;80(2):224-233. doi: 10.1097/QAI.0000000000001908.

4.

Efficacy and safety of tenofovir disoproxil fumarate versus low-dose stavudine over 96 weeks: a multi-country randomised, non-inferiority trial.

Venter WDF, Kambugu A, Chersich MF, Becker S, Hill A, Arulappan N, Moorhouse M, Majam M, Akpomiemie G, Sokhela S, Poongulali S, Feldman C, Duncombe C, Brown Ripin DH, Kumarasamy N.

J Acquir Immune Defic Syndr. 2018 Nov 12. doi: 10.1097/QAI.0000000000001908. [Epub ahead of print]

PMID:
30422900
5.

Household food security in an urban slum: Determinants and trends.

Dharmaraju N, Mauleshbhai SS, Arulappan N, Thomas B, Marconi DS, Paul SS, Mohan VR.

J Family Med Prim Care. 2018 Jul-Aug;7(4):819-822. doi: 10.4103/jfmpc.jfmpc_185_17.

6.

CD4 cell count variability with repeat testing in South Africa: Should reporting include both absolute counts and ranges of plausible values?

Daniel Francois Venter W, Chersich MF, Majam M, Akpomiemie G, Arulappan N, Moorhouse M, Mashabane N, Glencross DK.

Int J STD AIDS. 2018 Nov;29(11):1048-1056. doi: 10.1177/0956462418771768. Epub 2018 May 11.

PMID:
29749876
7.

Is laboratory screening prior to antiretroviral treatment useful in Johannesburg, South Africa? Baseline findings of a clinical trial.

Venter WDF, Majam M, Akpomiemie G, Arulappan N, Moorhouse M, Mashabane N, Chersich MF.

BMC Public Health. 2017 Jul 4;17(Suppl 3):445. doi: 10.1186/s12889-017-4353-1.

8.

Molecular diagnosis of maturity onset diabetes of the young in India.

Nair VV, Chapla A, Arulappan N, Thomas N.

Indian J Endocrinol Metab. 2013 May;17(3):430-41. doi: 10.4103/2230-8210.111636.

9.

A prospective assessment of dietary patterns in Muslim subjects with type 2 diabetes who undertake fasting during Ramadan.

Vasan SK, Karol R, Mahendri NV, Arulappan N, Jacob JJ, Thomas N.

Indian J Endocrinol Metab. 2012 Jul;16(4):552-7. doi: 10.4103/2230-8210.98009.

10.

Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial.

Karim QA, Kharsany AB, Frohlich JA, Baxter C, Yende N, Mansoor LE, Mlisana KP, Maarschalk S, Arulappan N, Grobler A, Sibeko S, Omar Z, Gengiah TN, Mlotshwa M, Samsunder N, Karim SS.

Trials. 2011 Mar 7;12:67. doi: 10.1186/1745-6215-12-67.

11.

Co-enrollment in multiple HIV prevention trials - experiences from the CAPRISA 004 Tenofovir gel trial.

Karim QA, Kharsany AB, Naidoo K, Yende N, Gengiah T, Omar Z, Arulappan N, Mlisana KP, Luthuli LR, Karim SS.

Contemp Clin Trials. 2011 May;32(3):333-8. doi: 10.1016/j.cct.2011.01.005. Epub 2011 Jan 26.

12.

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D; CAPRISA 004 Trial Group.

Science. 2010 Sep 3;329(5996):1168-74. doi: 10.1126/science.1193748. Epub 2010 Jul 19. Erratum in: Science. 2011 Jul 29;333(6042):524.

13.

Knowledge, attitude and practice related to medically unexplained symptoms among physicians.

Vijayaprasad G, Mathew AJ, Radhakrishnan S, Arulappan N, Christa JA, Jacob KS.

Natl Med J India. 2009 Sep-Oct;22(5):279. No abstract available.

PMID:
20334056

Supplemental Content

Loading ...
Support Center